Table 7.
Known-groups validity of EQ-5D-3L and EQ-5D-5L index scores in AD patients
| Outcome measures | EQ-5D-5L | EQ-5D-3L | REb | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Mean (SD) | Median (Q1-Q3) | p-valuea | ES | n | Mean (SD) | Median (Q1–Q3) | p-valuea | ES | ||
| IGA | |||||||||||
| Clear | 5 | 0.95 (0.09) | 1.00 (0.96–1.00) | < 0.001 | 0.105 | 5 | 0.97 (0.07) | 1.00 (1.00–1.00) | < 0.001 | 0.108 | 0.978 |
| Minimal | 27 | 0.93 (0.11) | 0.97 (0.91–1.00) | 27 | 0.93 (0.11) | 1.00 (0.88–1.00) | |||||
| Mild | 32 | 0.91 (0.08) | 0.92 (0.87–0.96) | 32 | 0.87 (0.09) | 0.88 (0.80–0.96) | |||||
| Moderate | 108 | 0.82 (0.20) | 0.88 (0.76–0.96) | 108 | 0.85 (0.13) | 0.82 (0.80–0.96) | |||||
| Marked | 41 | 0.70 (0.32) | 0.83 (0.49–0.92) | 41 | 0.78 (0.20) | 0.80 (0.72–0.90) | |||||
| Severe | 5 | 0.77 (0.07) | 0.79 (0.75–0.80) | 5 | 0.70 (0.15) | 0.72 (0.55–0.82) | |||||
| EASI | |||||||||||
| Clear (0.0–0.1) | 5 | 0.80 (0.33) | 0.96 (0.80–1.00) | < 0.001 | 0.083 | 5 | 0.93 (0.11) | 1.00 (0.85–1.00) | < 0.001 | 0.080 | 1.033 |
| Mild (0.2–5.9) | 46 | 0.92 (0.10) | 0.96 (0.88–1.00) | 46 | 0.91 (0.10) | 0.96 (0.82–1.00) | |||||
| Moderate (6–22.9) | 118 | 0.82 (0.21) | 0.90 (0.77–0.96) | 118 | 0.85 (0.14) | 0.88 (0.80–0.96) | |||||
| Severe (23–72) | 49 | 0.74 (0.28) | 0.85 (0.67–0.92) | 49 | 0.78 (0.18) | 0.80 (0.78–0.85) | |||||
| oSCORAD | |||||||||||
| Clear (0–7.9) | 8 | 0.97 (0.07) | 1.00 (0.99–1.00) | < 0.001 | 0.099 | 8 | 0.98 (0.05) | 1.00 (1.00–1.00) | < 0.001 | 0.103 | 0.966 |
| Mild (8–23.9) | 38 | 0.91 (0.11) | 0.94 (0.87–1.00) | 38 | 0.90 (0.10) | 0.93 (0.82–1.00) | |||||
| Moderate (24–37.9) | 73 | 0.86 (0.17) | 0.92 (0.81–0.97) | 73 | 0.86 (0.12) | 0.88 (0.80–0.96) | |||||
| Severe (38–83) | 99 | 0.76 (0.26) | 0.85 (0.65–0.92) | 99 | 0.80 (0.17) | 0.82 (0.78–0.90) | |||||
| DLQI | |||||||||||
| No effect (0–1) | 15 | 0.99 (0.01) | 1.00 (1.00–1.00) | < 0.001 | 0.489 | 15 | 0.99 (0.03) | 1.00 (1.00–1.00) | < 0.001 | 0.384 | 1.275 |
| Small effect (2–5) | 37 | 0.96 (0.05) | 1.00 (0.93–1.00) | 37 | 0.94 (0.09) | 1.00 (0.90–1.00) | |||||
| Moderate effect (6–10) | 40 | 0.93 (0.08) | 0.94 (0.92–0.96) | 40 | 0.91 (0.07) | 0.90 (0.88–1.00) | |||||
| Very large effect (11–20) | 76 | 0.80 (0.17) | 0.84 (0.76–0.92) | 76 | 0.82 (0.11) | 0.82 (0.80–0.88) | |||||
| Extremely large effect (21–30) | 50 | 0.62 (0.29) | 0.66 (0.45–0.85) | 50 | 0.73 (0.19) | 0.80 (0.62–0.82) | |||||
DLQI Dermatology Life Quality Index, EASI Eczema Area and Severity Index, ES effect size, IGA Investigator Global Assessment, oSCORAD objective Scoring Atopic Dermatitis, RE relative efficiency;
aMann–Whitney test or Kruskal–Wallis test, where a p < 0.05 was considered statistically significant
bRelative efficiency compared to the EQ-5D-3L